Cooperative Agreement U01AI141310

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $499,754 to Nuravax, Inc. to evaluate the safety, tolerability, and immunogenicity of their adjuvanted preventive dual AB/tau vaccine, DUVAX, in healthy human volunteers. The award will fund a randomized, double-blind, placebo-controlled study to assess DUVAX's safety and ability to generate an immune response in participants aged 40-65. This research builds on preclinical studies...

This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $4,472,279 to evaluate the safety and immunogenicity of a preventive tau vaccine, AV-1980R/A, in cognitively unimpaired individuals with preclinical Alzheimer's disease. The 5-year award, effective August 1, 2025, will enable the development of an effective preventive vaccination strategy for future clinical trials. The awardee, Institute For Molecular Medicine Inc., will conduct a...

This $677,777 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will support a study examining the impact of HIV status, age, and chronic immune activation on responses to the pneumococcal conjugate vaccine (PCV20) among older adults living with and without HIV. The study will measure acute (30-day) and long-term (2-year) immune responses following PCV20 vaccination across four participant groups: 1) older adults living with HIV, 2) older HIV-uninfected...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855) provides $1,172,336.00 to the University of Massachusetts Medical School over a 5-year period starting on August 19, 2024. The goal of the research is to investigate how distinct age-associated B cell subsets can protect the aged from influenza. Specifically, the project will determine the potential of different...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded Orlance, Inc., a woman-owned small business, a $300,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop an enhanced seasonal influenza DNA vaccine. The project aims to combine the advantages of a closely matched seasonal influenza vaccine with a universal influenza vaccine to provide more robust and durable protection, especially for the elderly and immunocompromised...

This Project Grant from the National Institutes of Health National Institute on Aging provided $227,436.88 to study the role of neutrophils in the age-driven decline of anti-pneumococcal vaccine responses. The Research Foundation for the State University of New York served as the awardee and Sponsored Projects Services as the vendor to carry out the research from June 15, 2021 to September 29, 2021. The objectives of the research were to test the role of neutrophils as effectors in the decline...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $249,276 to the University of San Francisco (USF) to assess the real-world effectiveness of maternal respiratory syncytial virus (RSV) vaccination. The project aims to evaluate the impact of the recently licensed maternal RSV vaccine in preventing RSV-associated lower respiratory tract infections (LRTIs) in infants,...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $456,390 to Wake Forest University Health Sciences to conduct research on regulating the immune response to an influenza vaccine in young infants. The key objectives are to understand how varying the duration of antigen delivery impacts the infant B and T cell responses, with the goal of improving the efficacy of influenza vaccines...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $528,660 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of Pittsburgh to discover human HLA T cell epitopes in human metapneumovirus (HMPV). HMPV is a leading cause of lower respiratory infection globally, and this research aims to characterize the human T cell response to HMPV to guide safe and effective vaccine development. The project will use HLA-transgenic mouse models and...

The University of Missouri System, under a $650,000 project grant from the USDA National Institute of Food and Agriculture (NIFA) Agriculture and Food Research Initiative (AFRI) program, is developing safe and effective live attenuated swine influenza vaccines using Newcastle disease virus (NDV) as the vector. The project aims to address the challenges with current swine influenza vaccines, which often fail to provide cross-protection against diverse virus strains. The key products and...